Shares of McKesson Corp. MCK dropped 0.03% to $508.00 Friday, on what proved to be an all-around mixed trading session for ...

The latest trading day saw McKesson (MCK) settling at $508, representing a -0.03% change from its previous close.

McKesson Corporation MCK is well-poised for growth in the coming quarters, courtesy of its strong Biologics business. The ...

Today, Benzinga's options scanner identified 12 options transactions for McKesson. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 58% being bullish and 25% ...

McKesson boasts solid revenue and EPS growth, supported by AI integration. Click here to read what offers a compelling ...

In the latest trading session, McKesson (MCK) closed at $508.16, marking a -0.68% move from the previous day. This change lagged the S&P 500's 1.7% gain on the day. On the other hand, the Dow ...

Two drug distribution companies at one point controlled 60% of the prescription opioid market in the Baltimore area, sending ...

McKesson (MCK) stock falls as company sets Q2 outlook below expectations due to higher tax rate, but reaffirms full-year ...

The city of Baltimore is scheduled to go to trial this week in its $11 billion lawsuit accusing drugmaker Johnson & Johnson ...

When Nancy Avila retired as CIO & CTO of McKesson in January of 2024, she thought her days in operational roles were over.

Analyst Allen Lutz from Bank of America Securities maintained a Buy rating on McKesson (MCK – Research Report) and keeping the price ...

Shares of McKesson Corp. MCK shed 1.14% to $513.91 Tuesday, on what proved to be an all-around mixed trading session for the ...